SCHEMBL19499655

SCHEMBL19499655

C/C=C(/C)C(=O)OC1C(O)C(CO)OC(OC2OC(CO)C(O)C(OC(=O)/C(C)=C\C)C2O)C1O

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LGALS8 O00214 9/20 0.51
▸ PTPN1 P18031 1/20 0.40
▸ LGALS3 P17931 3/20 0.37
▸ LGALS9 O00182 2/20 0.37
▸ LGALS1 P09382 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ LGALS4 P56470 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SELE P16581 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ SLC28A3 Q9HAS3 1/20 0.36
▸ LGALS7; LGALS7B P47929 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29378663 1.00 LGALS8 (0.51) LGALS8PTPN1LGALS3LGALS9LGALS1
SCHEMBL24495271 0.96 LGALS8 (0.48) LGALS8PTPN1LGALS3LGALS9LGALS1
SCHEMBL24495028 0.96 LGALS8 (0.48) LGALS8PTPN1LGALS3L3MBTL1LGALS4
SCHEMBL29375702 0.95 LGALS8 (0.47) LGALS8PTPN1LGALS3LGALS9LGALS1
SCHEMBL19499656 0.95 LGALS8 (0.47) LGALS8PTPN1LGALS3LGALS9LGALS1
SCHEMBL24495058 0.92 LGALS8 (0.45) LGALS8PTPN1LGALS3LGALS9LGALS1
SCHEMBL24494995 0.91 LGALS8 (0.44) LGALS8PTPN1LGALS3LGALS9LGALS1
SCHEMBL29379207 0.90 LGALS8 (0.45) LGALS8LGALS3LGALS9LGALS1LGALS4
SCHEMBL29376308 0.88 AMY1A (0.39) LGALS8LGALS3LGALS9LGALS1L3MBTL1
SCHEMBL19499653 0.88 AMY1A (0.39) LGALS8LGALS3LGALS9LGALS1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177507-A1 NOVEL COMPOUND AND USE OF SAME NAGASE & CO., LTD. (JP) 2022-06-09 — — US disclosed
US-10202627-B2 Method for producing trehangelin THE KITASATO INSTITUTE (JP) 2019-02-12 — — US disclosed
US-20170306371-A1 METHOD FOR PRODUCING TREHANGELIN NAGASE & CO., LTD. (JP) 2017-10-26 — — US disclosed
US-20170306371-A1 METHOD FOR PRODUCING TREHANGELIN NAGASE & CO., LTD. (JP) 2017-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177507-A1 NOVEL COMPOUND AND USE OF SAME TXNRD2, GPX4, GPX1 LGALS8 3562/4885PTPN1 4705/4885LGALS3 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback